TVRD – tvardi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Tvardi Therapeutics (TVRD) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium [Yahoo! Finance]
Tvardi Therapeutics (TVRD) had its "buy" rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics (TVRD) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "equal weight" rating on the stock.
Form S-8 Tvardi Therapeutics,
Form POS EX Tvardi Therapeutics,
Form 424B3 Tvardi Therapeutics,
Form 10-K Tvardi Therapeutics, For: Dec 31
Form 8-K Tvardi Therapeutics, For: Mar 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.